ONYX LIQUID EMBOLIC SYSTEM
Ev3 Neurovascular · Decision date Jul 21, 2005
What did the FDA approve?
The FDA recorded approval of premarket application P030004 for the Onyx Liquid Embolic System, submitted by Ev3 Neurovascular, on 2005-07-21. The product is classified as an injectable embolic agent under product code MFE, in the neurology specialty. The approval statement describes the device as indicated for presurgical embolization of brain arteriovenous malformations, a scope attributed to the 2005 decision and not asserted here as current labeling.
This is an original approval rather than a supplement, so no changed component or modified item is recorded in the source. Details of device composition, delivery components, patient-selection criteria, dosing and procedural instructions are not present in the available record and would reside in the original FDA documents, which were not supplied. No clinical or comparative conclusions are drawn.
FDA approval order statement
APPROVAL FOR THE ONYX LIQUID EMBOLIC SYSTEM (LES). THE DEVICE IS INDICATED FOR PRESURGICAL EMBOLIZATION OF BRAIN ARTERIOVENOUS MALFORMATIONS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jul 21, 2005
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030004
- Regulatory pathway
- Premarket approval application
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- Decision code
- APPR
- Decision date
- Jul 21, 2005
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, injectable, embolic.
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P030004 received
Application receipt date recorded by FDA.
P030004 · FDA decision
APPR
P030004/S039 · Related supplement
Onyx Liquid Embolic System (Onyx LES)
Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Onyx Liquid Embolic System (Onyx LES)P030004/S039 | Ev3 Neurovascular | PMA supplement | Oct 14, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records